China Resources Boya Bio pharmaceutical Group Co Ltd (300294) — Net Asset Quality Index
China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has a Net Asset Quality Index of 88.8% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥8.41 Billion minus total liabilities of CN¥942.80 Million yields net assets of CN¥7.46 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read China Resources Boya Bio pharmaceutical (300294) total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
China Resources Boya Bio pharmaceutical Group Co Ltd Net Asset Quality Index Over Time (2008–2025)
This chart shows how China Resources Boya Bio pharmaceutical Group Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the index stands at 88.8%, representing net assets of CN¥7.46 Billion against total assets of CN¥8.41 Billion CNY. For live market cap and overall valuation, see 300294 market cap overview.
Annual Net Asset Quality Index for China Resources Boya Bio pharmaceutical Group Co Ltd (2008–2025)
The table below presents the year-by-year Net Asset Quality Index for China Resources Boya Bio pharmaceutical Group Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check 300294 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 86.5% | CN¥7.46 Billion | CN¥8.63 Billion | CN¥1.16 Billion | ▼ -2.6 pp |
| 2024 | 89.1% | CN¥7.49 Billion | CN¥8.40 Billion | CN¥913.38 Million | ▼ -4.4 pp |
| 2023 | 93.5% | CN¥7.32 Billion | CN¥7.83 Billion | CN¥508.07 Million | ▲ +2.8 pp |
| 2022 | 90.7% | CN¥7.28 Billion | CN¥8.03 Billion | CN¥748.35 Million | ▼ -0.1 pp |
| 2021 | 90.8% | CN¥6.92 Billion | CN¥7.62 Billion | CN¥701.30 Million | ▲ +9.5 pp |
| 2020 | 81.3% | CN¥4.19 Billion | CN¥5.16 Billion | CN¥966.08 Million | ▲ +5.4 pp |
| 2019 | 75.9% | CN¥3.99 Billion | CN¥5.26 Billion | CN¥1.27 Billion | ▲ +1.6 pp |
| 2018 | 74.3% | CN¥3.77 Billion | CN¥5.07 Billion | CN¥1.30 Billion | ▲ +6.6 pp |
| 2017 | 67.7% | CN¥2.48 Billion | CN¥3.67 Billion | CN¥1.19 Billion | ▼ -20.4 pp |
| 2016 | 88.1% | CN¥2.13 Billion | CN¥2.42 Billion | CN¥287.30 Million | ▲ +0.9 pp |
| 2015 | 87.2% | CN¥1.91 Billion | CN¥2.19 Billion | CN¥280.11 Million | ▼ -3.6 pp |
| 2014 | 90.8% | CN¥923.93 Million | CN¥1.02 Billion | CN¥93.90 Million | ▲ +6.5 pp |
| 2013 | 84.3% | CN¥846.62 Million | CN¥1.00 Billion | CN¥157.85 Million | ▼ -12.4 pp |
| 2012 | 96.7% | CN¥751.60 Million | CN¥777.41 Million | CN¥25.80 Million | ▲ +17.4 pp |
| 2011 | 79.3% | CN¥262.67 Million | CN¥331.15 Million | CN¥68.48 Million | ▲ +12.4 pp |
| 2010 | 66.9% | CN¥197.44 Million | CN¥295.23 Million | CN¥97.79 Million | ▲ +14.9 pp |
| 2009 | 52.0% | CN¥164.49 Million | CN¥316.43 Million | CN¥151.93 Million | ▲ +9.3 pp |
| 2008 | 42.7% | CN¥63.79 Million | CN¥149.28 Million | CN¥85.49 Million | — |